Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.42 |
| ▸ | AKT1 | P31749 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745352 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL23230880 | 0.82 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL29782279 | 0.82 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL29745383 | 0.81 | NPC1 (0.48) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL23215905 | 0.81 | NPC1 (0.48) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL29745603 | 0.81 | NPC1 (0.48) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL23216119 | 0.81 | NPC1 (0.48) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL23215909 | 0.81 | NPC1 (0.48) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL25015773 | 0.80 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3AKT1 | |
| SCHEMBL13476451 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | SLC6A2 1553/4885SLC6A4 1866/4885SLC6A3 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.